CAR T-cells are primarily used for the treatment of certain types of blood cancers, particularly leukemia and lymphoma. They have shown remarkable success in treating relapsed or refractory cases of acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL), among others. Ongoing research aims to explore the potential use of CAR T-cells for other types of […]

CAR T-cells are a type of immune cell engineered to express chimeric antigen receptors (CARs) on their surface. These CARs are synthetic proteins designed to recognize and bind to specific antigens present on cancer cells. CAR T-cell therapy involves the collection of a patient’s T-cells, genetic modification in the laboratory to express CARs, and then […]

The duration of CAR T-cells’ presence in the body varies from patient to patient and depends on multiple factors. Typically, infused CAR T-cells can persist in the body for months to years after treatment. However, their persistence may decline over time. Despite this, some CAR T-cells may remain in the body as memory T-cells, providing […]

CAR T-cells work by recognizing and targeting specific cancer cells in the body. They are engineered in a laboratory to express chimeric antigen receptors (CARs) on their surface. These CARs allow the T-cells to bind to cancer cells that express the corresponding antigen. Once the CAR T-cells are infused back into the patient, they recognize […]

Yes, CAR T-cells can proliferate in the body. After infusion into the patient, CAR T-cells continue to multiply and expand in numbers, creating a strong and sustained immune response against the targeted cancer cells. This proliferation is essential for the CAR T-cells to effectively locate and destroy cancer cells throughout the body. However, excessive proliferation […]

CAR T-cells can be engineered from either CD4+ T-cells or CD8+ T-cells, both of which are subtypes of T-cells with distinct functions. CD4+ T-cells play a role in coordinating the immune response and supporting other immune cells, while CD8+ T-cells are primarily responsible for directly killing infected or cancerous cells. Depending on the specific cancer […]

Yes, CAR T-cells used in CAR T-cell therapy are typically autologous, meaning they are derived from the patient’s own immune cells. During the treatment process, T-cells are collected from the patient through leukapheresis, genetically engineered to express chimeric antigen receptors (CARs) and then infused back into the patient’s body. Using autologous CAR T-cells reduces the […]

A chimeric antigen receptor (CAR) is a synthetic protein designed to enable T-cells, a type of immune cell, to recognize and target specific cancer cells. CARs are engineered in the laboratory by combining different components from various proteins. They typically consist of an antigen-binding domain, which determines the CARs specificity for a particular cancer cell […]

Chimeric antigen receptors (CARs) are synthetic receptors engineered to enable T-cells to recognize and target specific cancer cells. CAR T-cell therapy involves modifying a patient’s T-cells to express these CARs on their surface. The CARs consist of an antigen-binding domain that recognizes the cancer cell’s antigen, a transmembrane domain that anchors the receptor to the […]